Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
Marseille, France, May 1, 2019, 7:00 AM CEST
Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 22, 2019, at 11:00 AM in its headquarters, 117 avenue de Luminy, F-13009 Marseille.
The Notice of Meeting of this Shareholders’ Meeting was published on April 15, 2019, in the French official legal bulletin (“BALO”). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available on the Company’s website.
All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be published on the Company’s website as of today.
The 2018 Reference Document (in French) and Financial Report (included in the Reference Document) was released on April 30, 2019 under number D.19-0444, and is available on the website of the Company ( http://www.innate-pharma.com ) as well as on the website of the AMF, the French stock-market authorities ( www.amf-france.org ).
Hard copies are available upon request to the investor relations department of the Company.
An English translation of the 2018 Reference Document will be made available on Innate Pharma’s website during the month of May 2019.
Precision regarding the AGM:
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend.
Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.
Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by registered letter, addressed to the registered office, or by e-mail to email@example.com ).
Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French “Code de Commerce”) by sending a request:
# by regular mail to Innate Pharma, Shareholders Services, 117 avenue de Luminy, BP 30191, F-13009 Marseille, France or # by e-mail to firstname.lastname@example.org.
About Innate Pharma:
Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca.
Based in Marseille, France, Innate Pharma is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com.
Information about Innate Pharma shares:
ISIN code FR0010331421 Ticker code IPH LEI 9695002Y8420ZB8HJE29
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Investors International Media Innate Pharma Consilium Strategic Communications Dr. Markus Metzger / Danielle Spangler / Mary-Jane Elliott / Jessica Hodgson Jérôme Marino Tel.: +33 (0)4 30 30 30 30 Tel.: +44 (0)20 3709 5700 email@example.com InnatePharma@consilium-comms.com French Media ATCG Partners Solène Moulin Tel.: +33 (0)9 81 87 46 72 firstname.lastname@example.org
-- 190430 IPH_PR AG-DDR EN